Prevail Therapeutics Inc was Precision Biosciences’s largest revenue line in fiscal 2023, bringing in $26.00M of $48.70M (53%).
| Counterparty Name | FY 2022 | FY 2023 |
|---|---|---|
| Prevail Therapeutics Inc | $15.60M | $26.00M |
| Novartis Pharma Ag | $9.50M | $22.70M |
| Total | $25.10M | $48.70M |
Precision Biosciences brought in $48.70M from its two revenue lines in fiscal 2023, the year ended December 31, 2023. That was up 94.0% from $25.10M in fiscal 2022. Prevail Therapeutics Inc was the largest at $26.00M (53.4%), ahead of Novartis Pharma Ag at $22.70M (46.6%).
Compared with fiscal 2022, Novartis Pharma Ag grew 138.9% to $22.70M and Prevail Therapeutics Inc grew 66.7% to $26.00M.
Precision Biosciences (DTIL) reports its revenue by counterparty name. In fiscal 2023, Prevail Therapeutics Inc was its largest revenue line, bringing in $26.00M (53.4% of the total), followed by Novartis Pharma Ag at $22.70M (46.6%).
Prevail Therapeutics Inc was Precision Biosciences' largest revenue line in fiscal 2023, bringing in $26.00M, or 53.4% of the $48.70M total across its two revenue lines.
Novartis Pharma Ag grew faster than Prevail Therapeutics Inc in fiscal 2023, up 138.9% from $9.50M to $22.70M. Prevail Therapeutics Inc grew 66.7% to $26.00M.
Every figure comes from Precision Biosciences' annual financial filings, as reported. Each line keeps the name Precision Biosciences gives it, and years follow its fiscal calendar.
Precision Biosciences' revenue by counterparty name goes back to fiscal 2022, with figures through fiscal 2023. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.